

Curemark is a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of neurological disorders.

Our pipeline includes our lead drug candidate, CM-AT, which is in a Phase III clinical trial for Autism, and is referred to as the Blüm™ Study. Our pipeline also includes clinical-stage and preclinical programs for treating ADHD, Parkinson's, schizophrenia and addiction.

The reason why we come to work every day is simple: we are motivated first and foremost by our desire to understand and address the needs of patients and their families.